Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer
1998

Hepatic Steatosis in Colorectal Cancer Patients on Chemotherapy

Sample size: 21 publication Evidence: moderate

Author Information

Author(s): PD Peppercorn, RH Reznek, P Wilson, ML Slevin, RK Gupta

Primary Institution: St Bartholomew's Hospital

Hypothesis

What is the frequency and severity of fatty change of the liver in patients receiving 5-FU and folinic acid?

Conclusion

Hepatic steatosis occurs commonly in patients receiving 5-FU and folinic acid and can complicate the assessment of liver metastases.

Supporting Evidence

  • Forty-seven percent of patients developed hepatic steatosis during treatment.
  • The mean fall in liver attenuation was 13.2 HU.
  • Eleven patients had a change in liver attenuation of less than 10 HU.
  • Overall, there was a significant difference in liver attenuation of all 21 patients before and after treatment.

Takeaway

Some cancer patients on a specific chemotherapy can develop fat in their liver, which can make it hard for doctors to see if the treatment is working.

Methodology

Twenty-seven patients were studied with CT scans before and after chemotherapy, and those with progressive disease were excluded.

Potential Biases

Potential bias in patient selection due to exclusion criteria.

Limitations

The study excluded patients with known causes of fatty liver and those with progressive disease, which may limit generalizability.

Participant Demographics

21 patients (11 male, 10 female, age 37-74 years).

Statistical Information

P-Value

0.0019

Statistical Significance

p=0.0019

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication